MARC details
| 000 -LEADER |
|---|
| fixed length control field |
02938nam a22003497a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
200826s20202020 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
1923-2829 |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.14740/cr1066 [doi] |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
PMC7295562 [pmc] |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
32595807 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
Efficacy of Allopurinol in Cardiovascular Diseases: A Systematic Review and Meta-Analysis. |
| 251 ## - Source |
|---|
| Source |
Cardiology Research. 11(4):226-232, 2020 Aug. |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
Cardiol Res. 11(4):226-232, 2020 Aug. |
| 253 ## - Journal Name |
|---|
| Journal name |
Cardiology research |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Year |
2020 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Manufacturer |
FY2021 |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
|---|
| Publication status |
ppublish |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2020-08-26 |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Background: Given current evidence, the use of allopurinol for the prevention of major cardiovascular events (acute cardiovascular syndrome (ACS) or cardiovascular mortality) in patients undergoing coronary artery bypass graft (CABG), after index ACS or heart failure remains unknown. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Conclusions: Periprocedural use of allopurinol might be associated with a significant reduction in the odds of ACS and cardiovascular mortality in patients undergoing CABG. Allopurinol, however, offers no long-term benefits in terms of secondary prevention of ACS or mortality. Larger scale studies are needed to validate our findings. Copyright 2020, Ullah et al. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Methods: Multiple databases were queried to identify studies comparing the efficacy of allopurinol in patients undergoing CABG, after ACS or heart failure. The unadjusted odds ratio (OR) was calculated using a random effect model. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Results: A total of nine studies comprising 850 patients (allopurinol 480, control 370) were identified. The pooled OR of periprocedural ACS (OR: 0.25, 95% confidence interval (CI): 0.06 - 0.96, P = 0.05) and cardiovascular mortality (OR: 0.22, 95% CI: 0.07 - 0.71, P = 0.01) was significantly lower in patients receiving allopurinol during CABG compared to patients in the control group. The overall number needed to treat (NNT) to prevent one ACS event was 11 (95% CI: 7 - 28), while the NNT to prevent one death was 24 (95% CI: 13 - 247). By contrast, the odds of cardiovascular mortality in the allopurinol group were not significantly different from the control group in patients on long-term allopurinol after ACS or heart failure (OR: 0.33, 95% CI: 0.01 - 8.21, P = 0.50) and (OR: 1.12, 95% CI: 0.39 - 3.20, P = 0.83), respectively. Similarly, the use of allopurinol did not reduce the odds of recurrent ACS events at 2 years (OR: 0.32, 95% CI: 0.03 - 3.18, P = 0.33). |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
IN PROCESS -- NOT YET INDEXED |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
|---|
| Institution |
MedStar Union Memorial Hospital |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Journal Article |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Khan, Rozi |
| 790 ## - Authors |
|---|
| All authors |
Alraies MC, Basyal B, Fischman DL, Khan R, Khanal S, Minalyan A, Munir S, Ullah W |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="https://dx.doi.org/10.14740/cr1066">https://dx.doi.org/10.14740/cr1066</a> |
| Public note |
https://dx.doi.org/10.14740/cr1066 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Article |
